Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 14, 2021 07:00 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Expansion of Scientific Advisory Board With Appointment of Leading Global Experts in Dermatology and Immunology

MENLO PARK, Calif. and SINGAPORE, Oct. 14, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
August 04, 2021 07:00 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference

SINGAPORE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
July 13, 2021 07:00 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures

SINGAPORE, July 13, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
April 22, 2021 07:51 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

SINGAPORE, April 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
March 03, 2021 00:42 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Pricing of Public Offering of American Depositary Shares

SINGAPORE, March 03, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
January 26, 2021 07:30 ET | Source: ASLAN PHARMACEUTICALS LIMITED

New Research Published in Toxicology in Vitro Provides Insight Into the Hepatotoxicity of DHODH Inhibitors Suggesting ASLAN003 Has the Potential to Be Best-In-Class

— New research shows ASLAN003 to have the lowest potential for hepatotoxicity of the compounds tested despite being one of the most potent DHODH inhibitors — Data differentiates ASLAN003 from first...
October 16, 2020 05:25 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions

-- ASLAN believes ASLAN003 has the potential to be the most potent oral inhibitor of DHODH currently in development for autoimmune disease, more than 30 times more potent at inhibiting the DHODH...
March 18, 2020 05:18 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

SINGAPORE, March 18, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative...
December 03, 2019 01:00 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Pricing of $12.8 Million Public Offering of American Depositary Shares

SINGAPORE, Dec. 03, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that it has...
November 22, 2019 01:30 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Publication of Preclinical Data on ASLAN003 in AML in Haematologica Journal

SINGAPORE, Nov. 22, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that new preclinical...

Next Page keyboard_arrow_right